Search research articles
Contact Us
Filters
Showing results (241-250 of 244) with videos related to
Page
of 25
Sort By:
You have reached the last page of results.
This site can display upto 244 results.
Breast Cancer Research and Treatment
|
February 9, 2017
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study
M Higgins, G Curigliano, V Dieras, et al.
Brain, Behavior, and Immunity
|
June 4, 2018
Early life stress in mice is a suitable model for Irritable Bowel Syndrome but does not predispose to colitis nor increase susceptibility to enteric infections
A Riba, M Olier, S Lacroix-Lamandé, et al.
Nature Medicine
|
July 14, 1998
Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy
S Fleury, R J de Boer, G P Rizzardi, et al.
ESMO Open
|
November 16, 2016
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
R Gutzmer, L Rivoltini, E Levchenko, et al.
Page
of 25
Search research articles
Search
Showing results (241-250 of 244) with videos related to
Sort By:
Page
of 25
You have reached the last page of results.
This site can display upto 244 results.
Breast Cancer Research and Treatment
|
February 9, 2017
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study
M Higgins, G Curigliano, V Dieras, et al.
Brain, Behavior, and Immunity
|
June 4, 2018
Early life stress in mice is a suitable model for Irritable Bowel Syndrome but does not predispose to colitis nor increase susceptibility to enteric infections
A Riba, M Olier, S Lacroix-Lamandé, et al.
Nature Medicine
|
July 14, 1998
Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy
S Fleury, R J de Boer, G P Rizzardi, et al.
ESMO Open
|
November 16, 2016
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
R Gutzmer, L Rivoltini, E Levchenko, et al.
Page
of 25